Phenpromethamine (former brand name Vonedrine), also known as '''N,β-dimethylphenethylamine (MPPA, BMMPEA, β-Me-NMPEA, β,N-MePEA'''), is a sympathomimetic nasal decongestant of the phenethylamine group. It was previously marketed as a nasal inhaler from 1943 through 1960 but is no longer available. The medication is a stimulant and is banned by the World Anti-Doping Agency. It has been detected in dietary supplements starting in the 2010s.
Phenpromethamine (former brand name Vonedrine), also known as '''N,β-dimethylphenethylamine (MPPA, BMMPEA, β-Me-NMPEA, β,N-MePEA'), is a sympathomimetic nasal decongestant of the phenethylamine group. It was previously marketed as a nasal inhaler from 1943 through 1960 but is no longer available. The medication is a stimulant and is banned by the World Anti-Doping Agency. It has been detected in dietary supplements starting in the 2010s.
The drug is a monoamine releasing agent (MRA) similarly to β-phenethylamine, amphetamine, and other phenethylamines. It is the N-methyl derivative of β-methylphenethylamine (BMPEA) and the β-methyl derivative of N-methylphenethylamine (NMPEA). Phenpromethamine is known to act as a norepinephrine–dopamine releasing agent (NDRA), with values of 154nM for norepinephrine and 574nM for dopamine in rat brain synaptosomes, whereas serotonin was not reported.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).